The metabolic syndrome

Nutrition Bulletin

Volumn 29, Issue 1, 2004, Pages 36-43

  Nugent, Anne P ^a  

^a BRITISH NUTRITION FOUNDATION   (United Kingdom)

Author keywords

Diabetes; Hypertension; LIPGENE; Metabolic syndrome; OB AGE; Obesity

Indexed keywords

BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR DISEASE; DIET THERAPY; DYSLIPIDEMIA; EUROPEAN UNION; EXERCISE; FAT INTAKE; HEALTH CARE COST; HEALTH EDUCATION; HEALTH PRACTITIONER; HUMAN; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; LIFESTYLE; MEDICAL RESEARCH; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; REVIEW; RISK FACTOR;

EID: 1542300237     PISSN: 01419684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Aitman TJ, Gotoda T, Evans AL et al. (1997) Quantitative trait loci for cellular defects in glucose and fatty acid metabolism in hypertensive rats. Nature Genetics 16: 197-201.
2. Baier LJ, Sacchettini JC, Knowler WC et al. (1995) An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation, and insulin resistance. Journal of Clinical Investigation 95: 1281-7.
3. Balkau B & Charles MA (1999) Comments on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance. Diabetic Medicine 16: 442-3.
4. Barker DJ, Hales CN, Fall CH et al. (1993) Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 36: 62-7.
5. Blair SN, Cheng Y & Holder JS (2001) Is physical activity or physical fitness more important in defining health benefits? Medical Science Sports Exercise 33 (6): S379-99.
6. Bonora E, Kiechl S, Willeit J et al. (1998) Prevalence of insulin resistance in metabolic disorders. The Bruneck Study. Diabetes 47: 1643-9.
7. BNF (British Nutrition Foundation) (1999) Briefing Paper: N-3 Fatty Acids and Health. Blackwell Publishing, London.
8. BNF (British Nutrition Foundation) (2000) Task Force Report: Obesity. Task Force. Blackwell Publishing, London.
9. BNF (British Nutrition Foundation) (2004) Task Force Report: Cardiovascular Disease: Diet, Nutrition and Emerging Risk Factors. Blackwell Publishing, London, in press.
10. Buttriss J (2003) Metabolic syndrome: new research underway. Nutrition Bulletin 28 (4): 318-85.
11. Chait A, Brazg RL, Tribble DL et al. (1993) Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. American Journal of Medicine 94: 350-6.
12. Denke MA (2001) Connections between obesity and dyslipidemia. Current Opinion in Lipidology 12: 625-8.
13. Despres JP, Lamarche B, Mauriege P et al. (1996) Hyperinsulinemia as an independent risk factor for ischaemic heart disease. New England Journal of Medicine 334: 952-7.
14. Dineen SF & Gerstein HC (1997) The association of microalbuminuria and mortality in ono-insulin-dependent diabetes mellitus. A systematic overview of the literature. Archives of International Medicine 157: 1413-8.
15. Dunaif A (1997) Insulin resistance and the polycystic ovary syndrome: mechanisms and implications for pathogenesis. Endocrine Reviews 18: 774-800.
16. Eriksson JG, Forsen T, Tuomilehto J et al. (1999) Catch-up growth in childhood and death from coronary heart disease: longitudinal study. British Medical Journal 318: 427-31.
17. Festa A, D'Agostino JR, Howard G et al. (2000) Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102: 42-7.
18. Ford ES, Giles WH & Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. Journal of the American Medical Association 287: 356-9.
19. Gardner CD, Fortmann SP & Krauss RM (1996) Association of small low-dense lipoprotein particles with the incidence of coronary artery disease in mean and women. Journal of the American Medical Association 276: 872-81.
20. Groop L, Forsblom C, Lehtovireta M et al. (1996) Metabolic consequences of a family history of NIDDM (The Botnia Study): evidence for sex-specific parental effects. Diabetes 45: 1585-93.
21. Haffner SM, Stern MP, Hazuda HP et al. (1990) Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? Journal of the American Medical Association 263: 2893-8.
22. Hales CN, Barker DJ, Clark PM et al. (1991) Fetal and infant growth and impaired glucose tolerance at the age of 64. British Medical Journal 303: 1019-22.
23. Hattersley AT & Tooke JE (1999) The fetal insulin hypothesis: an alternative explanation of the association of low birth weight with diabetes and vascular disease. Lancet 253: 1789-92.
24. Hermansen K (2000) Diet, blood pressure and hypertension. British Journal of Nutrition 83 (1): S113-9.
25. Hulthe J, Bokemark L, Wikstrand J et al. (2000) The metabolic syndrome, LDL particle size, and atherosclerosis. The atherosclerosis and insulin resistance study. Arteriosclerosis Thrombosis Vascular Biology 20: 2140-7.
26. Isomaa B (2003) A major health hazard: the metabolic syndrome. Life Sciences 73: 2395-411.
27. Isomaa B, Almgren P, Tuomi T et al. (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24: 683-9.
28. Jaquet D, Gaboriau A, Czernichow P et al. (2000) Insulin resistance early in adulthood in subjects with intrauterine growth retardation. Journal of Clinical Endocrinology and Metabolism 85: 1401-6.
29. Jiang ZY, Lin Y-W, Clemont A et al. (1999) Characterisation of selective resistance to insulin signalling in the vasculature of obese Zucker (fa/fa) rats. Journal of Clinical Investigation 104: 447-57.
30. Knobler H, Schattner A, Zhornicki T et al. (1999) Fatty liver-an additional and treatable feature of the insulin resistance syndrome. Quarterly Journal of Medicine 92: 73-9.
31. Lakka HM, Laaksonen DE, Lakka TA et al. (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. Journal of the American Medical Association 288: 2709-16.
32. Lamarche B, Tchernof A, Mauriege P et al. (1997) Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischaemic heart disease. Journal of the American Medical Association 279: 1955-61.
33. Lean MEJ, Han TS & Morrison CE (1995) Waist circumference as a measure for indicating need for weight management. British Medical Journal 311: 158-61.
34. Lemieux I, Pascot A, Couillard C et al. (2000) Hypertriglyceridemic waist; a marker of the thergenic triad (hyperinsulinemia; hyperapolipoprotein B; small dense LDL) in men? Circulation 102: 179-84.
35. Maes HH, Neale MC & Eaves LJ (1997) Genetic and environmental factors in relative body weight and human adiposity. Behaviour Genetics 27: 325-51.
36. Mäkimattila A & Yki-Jarvinen H (2002) Endothelial dysfunction in human diabetes. Current Diabetes Reports 2: 26-36.
37. McFarlane SI, Banerji M & Sowers JR (2001) Insulin resistance and cardiovascular disease. Journal of Clinical Endocrinology 86: 713-8.
38. Meigs JB, D'Agostino RB Sr, Wilson PW et al. (1997) Risk variable clustering in the insulin resistance syndrome: the Framingham Off-spring Study. Diabetes 46: 1594-600.
39. Mykkänen L, Haffner SM, Kuusisto J et al. (1994) Microalbuminuria precedes the development of NIDDM. Diabetes 43: 552-7.
40. NIH (National Institute of Health) (2001) Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Institute of Health, Bethesda, MD. NIH Publication 01-3670.
41. Neel JV (1962) Diabetes mellitus: a 'thrifty' genotype rendered detrimental by 'progress'. American Journal of Human Genetics 14: 353-62.
42. Reaven GM (1988) Role of insulin resistance in human disease. Diabetes 37: 1595-607.
43. Reaven BM, Lithell H & Landberg L (1996) Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. New England Journal of Medicine 334: 374-81.
44. Ryan MCM & Thakore JH (2002) Physical consequences of schizophrenia and its treatment; the metabolic syndrome (mini review). Life Sciences 71: 239-57.
45. Scott CL (2003) Diagnosis, prevention and intervention for the metabolic syndrome. American Journal of Cardiology 92 (suppl.): 35i-42i.
46. Sharma AM, Moeller T & Engeli S (1999) Hypertension in obesity: its epidemiology, physiolopathology and treatment efforts. Deutsche medizinische Wochenschrift 124: 1337-41.
47. Sigurdardottir V, Fagerberg B & Hulthe J (2002) Circulating oxidised low-density lipoprotein is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year-old men (AIR study). Journal of International Medicine 252 (5): 440-7.
48. Stampfer MJ, Krauss RM, Ma J et al. (1996) A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. Journal of the American Medical Association 276: 882-8.
49. Taylor SI, Cama A, Accili D et al. (1992) Mutations in the insulin receptor gene. Endocrinology Reviews 13: 566-95.
50. Tchernof A, Lamarche B, Prud'Homme D et al. (1996) The dense LDL phenotype: association with plasma lipoprotein levels, visceral obesity and hyperinsulinemia in men. Diabetes Care 19: 629-37.
51. Tonkin R (2003) The X Factor: obesity and the metabolic syndrome. The Science and Public Affairs Forum.
52. Vague J (1953) La differenciation sexuelle humaine: ses incidences en pathologie. Masson, Paris, p. 386.
53. WHO (World Health Organization) (1999) Report of a WHO consultation: definition of metabolic syndrome in definition, diagnosis, and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus. World Health Organization, Department of Noncommunicable Disease Surveillance, Geneva.
54. Yusuf S, Gerstein H, Googwerf B et al. (2001) Ramipril and the development of diabetes. Journal of the American Medical Association 286: 1882-5.